NKG2D CAR T-cells (Zhejiang University)

NKG2D CAR T-cells (Zhejiang University) is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). Unlike traditional CAR-T therapies that typically utilize a single-chain variable fragment (scFv) for antigen recognition, this construct employs the full-length human NKG2D receptor as the extracellular binding domain. This approach allows the engineered T cells to recognize a broad spectrum of stress-induced NKG2D ligands, including MICA, MICB, and the ULBP family (ULBP1-6), which are frequently overexpressed on the surface of AML blasts but have limited expression on healthy tissues. The therapy is currently undergoing evaluation in a Phase 1 clinical trial (NCT04658004) to assess its safety, dose-related toxicity, and preliminary anti-leukemic activity in patients with NKG2D ligand-positive AML.

Other names

NKG2D CAR T-cellsNKG-2D CAR T-cellsNKG 2D CAR T-cellsNKG2D-targeted CAR-T cellsNKG-2D-targeted CAR-T cellsNKG 2D-targeted CAR-T cellsNKG2D CAR-TNKG-2D CAR-TNKG 2D CAR-T